Dystrophin Immunity in Duchenne's Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the first mini-dystrophin clinical trial (NCT00428935), completed in 2010, most parsimoniously failed due to immune responses developed against the transgene, which was delivered in the biceps muscle using the AAV2.5 vector [122].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [122]
In the citing paper
“To date, transgene immune responses in AAV gene therapy have been mostly reported in muscle-directed clinical trials [94, 115–119].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
In the citing paper
“In clinical trials, CD8+ T cell responses have been observed against dystrophin and α1-antitrypsin in treatment of Duchenne’s muscular dystrophy and α1-antitrypsin (AAT) deficiency, respectively (55, 56).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citation
Research works printed but not linked: 1
- Klein CJ, 1992, Am J Hum Genet, 50, 950
Cited by
Items 601–680 of 680
(2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834dd969
Phillips, W. D. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736726733.793571912
(2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834ccef6
Sahenk, Z., & Rodino‐Klapac, L. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6567-6_56
Self-citationNeuromuscular Cardiomyopathies
Kamdar, F. D., Mammen, P. P. A., & Garry, D. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-44577-9_12
(2010) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0b013e318204dfd1
Fehlings, M. G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734958350.793573257
Cell-Based and Gene-Based Therapy Approaches in Neuro-orthopedic Disorders: a Literature Review
Irajian, A. H., Presedo, A., Pasha, B. A., Ghasemi, M., Arabi, M., Abdi, S., Sheshtamed, M. F., & Nabian, M. H. (2022) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-022-00284-9
“In vector-associated cell therapy, immune response to the viral vector could prevent the delivery of the gene; even if the delivery of the gene is proper, in dystrophin knockout patients, the host immune system summons an Immune response to the functional dystrophin protein [51, 66].”
BackgroundCRISPR-Cas9 mediated endogenous utrophin upregulation improves Duchenne Muscular DystrophyPreprint
Guiraud, S., Dastidar, S., Mazed, F., Amor, F., Ralu, M., Cian, A. D., Richard, I., Ronzitti, G., Tedesco, F. S., & Amendola, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.18.536394
Normal and Aberrant Muscle Tissue Healing, Learning from Health and Disease
Kostek, M. C., & Liu, S. (2023) · OBM Genetics · doi:10.21926/obm.genet.2303192
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Detection of Cellular Immunity to Viral Capsids and Transgene Proteins
de la Rosa, M., & Tary‐Lehmann, M. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch11
Current Regulatory Landscape for Gene Therapy Product Development and the Role of Biomarkers
Salazar‐Fontana, L. I., & Havert, M. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch18 · Cited by 1
Molecular Genetic Therapies in the Muscular Dystrophies
Nicolau, S., & Flanigan, K. M. (2023) · Current clinical neurology · doi:10.1007/978-3-031-44009-0_18
Role of oxidised protein repair for skeletal muscle homeostasis
dos Santos, S. L. (2016) · theses.fr (ABES) · doi:10.70675/0cff38cez1fa3z4b26zbe64z1958addb2ca1
Explorations Multi-omiques dans les maladies neuromusculaires
Dabaj, I. (2023) · theses.fr (ABES) · doi:10.70675/120670afz0b80z472dzb00bz95793dadb289
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., Wu, H., Ma, S., Han, J., Bu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23665119
Even a Worm Will Turn: Immunity Following AAV Vector Administration
Patel, K., Khatri, A., & Somanathan, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_7
CD4 + T cells fuel the Duchenne cardiomyopathyPreprint
Gladow, N., Rizzo, G., Michel, T., Krammer, T., Saliba, A., Frantz, S., Ramos, G. C., Cochain, C., & Hofmann, U. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.30.684828
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., 吴红然, Ma, S., HAN, J., Bu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23665107
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., 吴红然, Ma, S., HAN, J., Bu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23665110
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049039
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049054
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., 吴红然, Ma, S., HAN, J., Bu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23665098
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., 吴红然, Ma, S., HAN, J., Bu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23665104
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049060
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049048
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049051
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049045
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049063
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049042
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049057
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., 吴红然, Ma, S., HAN, J., Bu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23665101
Han, X., Ji, G., Wang, N., Yi, L., Mao, Y., Deng, J., 吴红然, Ma, S., HAN, J., Bu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23665116
Correction du gène de la dystrophine avec les nucléases à doigts de zinc
Iyombe, J.-P. (2013) · Corpus Université Laval (Université Laval)
Tanaka, H., Nishiumi, N., Shirane, D., Kosegawa, Y., Siril, Y. J., & Akita, H. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00789
Shin, H.-S., Cho, S.-Y., Kwon, Y., Jung, S.-M., Seo, E. S., Son, Y. M., Kim, E. T., Kim, D., & Kim, K.-D. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1716928
“AAV-based gene therapies have since advanced to clinical testing in patients with muscular dystrophy (Mendell et al., 2010).”
Evaluation of protein expression and oxidative stress index in Duchenne muscular dystrophy
Rizk, S. K., Ezzat, E. M., Abuhegazy, A., & El‐Ghlban, S. (2026) · Pediatric Research · doi:10.1038/s41390-025-04585-x
Elimination of intramuscular immunoglobin accumulation alleviates Duchenne Muscular DystrophyPreprint
Zhang, L., Guo, W., Huang, M., Liang, Z. Y., Zhu, E., Li, G., Chang, C., Guo, X. S., Sun, W., Li, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.11.703666
“While significant progress has been made in dystrophin restoration, this approach faces many challenges, including delivery issues, incomplete understanding of toxicity( 60-62 ), limited efficacy, small patient segments, and high costs( 63, 64 ).”
Self-citationTherapeutic strategies targeting muscle stem cells in satellite cell-opathies
Garcia, P., Mokhtari, I., & Dumont, N. A. (2026) · Journal of Neuromuscular Diseases · doi:10.1177/22143602251414570
“231 Moreover, the ef fi cacy of AAV delivery is signi fi cantly reduced in dystrophic muscle due to ongoing cycles of myo-fi ber degeneration and regeneration, which lead to the loss of viral particles before they can achieve stable transduction, as well as reduced transgene transcription due to…”
Hardet, R., Wang, S.-H., Delignat, S., Blandin, M., Digigow, R. G., Gottwick, C., Heine, M., Mesquita, L., Fanzutti, M., Vocaturo, A.-L., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.009
“37,38 To evaluate the efficacy of TPCs to also induce tolerance in this other clinically relevant and more immunogenic situation, AAV8-Ova were injected intramuscularly (i.m.) at day 0, and mice received i.v. injection of an equimolar mixture of TPC-Ova-I and TPC-Ova-II at predefined time points,…”
Characterization of the P1.LSU/2 group II intron for its use in genomic targeting
Zerbato, M. (2012) · theses.fr (ABES) · doi:10.70675/4440f1e7zda74z4059za441z97951b6182b7
La modularité de la dysferline peut-elle permettre le développement d'approches thérapeutiques?
Barthélémy, F. (2013) · theses.fr (ABES) · doi:10.70675/b51efb0fz3b2ez406dz8b41za40ff9115334
Carpentier, M. (2013) · theses.fr (ABES) · doi:10.70675/fa69ca30zf46az45f1z9638z003bd41555e4
Latil, M. (2013) · theses.fr (ABES) · doi:10.70675/05468b01z26d3z4497za6b2z8a8bc4d00e4f
Lorant, J. (2016) · theses.fr (ABES) · doi:10.70675/87808109zf52cz4402z9da6z81f59cf2d98e · Cited by 1
The function of Activin receptor type IIB signaling in adult skeletal muscle
Relizani, K. (2014) · theses.fr (ABES) · doi:10.70675/20978d43z02f0z4a1ezb428zf5dab86d9abf
Brouilly, N. (2013) · theses.fr (ABES) · doi:10.70675/1ed77bd9z671dz4e71z8cd6z0f1390f03728
Propriétés de reconnaissance antigénique des lymphocytes T régulateurs CD4+ FOXP3+
Lalfer, M. (2015) · theses.fr (ABES) · doi:10.70675/64648159z6aa9z4b18z8768z8e24ccef8373
Bartolo, L. (2018) · theses.fr (ABES) · doi:10.70675/b32b9711za15dz4740z8481z0ba7dd36e8ee
Verdera, H. C. (2019) · theses.fr (ABES) · doi:10.70675/3d2d8524z211ez4408zbdfbz56c065f452a1
Le développement préclinique des tcDNA pour la Dystrophie Musculaire de Duchenne
Aupy, P. (2019) · theses.fr (ABES) · doi:10.70675/308d569bzf97az413bz805fzc8aaca0427df
Nan, X., Sun, J., Jiao, Y., Li, W., Chen, Y., Liu, Y., Xu, B., Yu, L., Guo, W., & Wu, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261432669 · Cited by 1
“78 Regional intravascular perfusion.”
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
A new DMD rat model : from characterization to therapy
Daoud, C. (2022) · theses.fr (ABES) · doi:10.70675/c15a9cf0zea1cz4e15z8a16zfac7e90d08c9
Creisméas, A. (2022) · theses.fr (ABES) · doi:10.70675/7e452f5az22a1z433az83a8z1fe23089846a
Nouvelle génération d’AAV : un mélange de chimie organique et de vectorologie
Lalys, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/b6df86c2z6520z473ez9e10ze1740b9bc3ae
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Jeanpierre, L., Pecquet, C., Saliba, H., Finard, P., Terry, S., Tavella, G., Guesmia, I., Boutin, S., Bertin, B., Benkhelifa‐Ziyyat, S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202541
“Depending on their maturation state and detection of pathogen-specific molecular patterns such as unmethylated CpG dinucleotides by Toll-like receptor 9, antigen presentation by DCs can result in either T cell tolerance or full activation and subsequent effector and memory T cell differentiation.”
Препятствия на пути к разработке генной терапии мышечной дистрофии Дюшенна
Kurshakova, E. V., Александровна, Л. О., & Вячеславович, Л. А. (2025) · Genes and Cells
Li, N., Li, Z., Zhang, Z., Xiahou, Z., Xiao, H., Wu, S., Xu, F., Liu, Q., Wu, Y., & Song, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08483-6
“Previous studies, including ours, have demonstrated that systemic delivery of AAV-micro-utrophin prevented myonecrosis without eliciting immunogenicity in murine and canine DMD models [23, 24, 32].”
Polat, M., Dinçer, S. A., & Terzi, Y. K. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017730
Nassour, H., Al_Shbailat, S. A., Ibrahim, A. S., Allan, A. M., Badie, M. S., Alnjoom, Q. M., Alrfou, M. J. F., Makhoul, G. E., Weis, M. G., Ahmad, R. K., et al. (2026) · Journal of Medical Genetics · doi:10.1136/jmg-2026-111649
Li, K., Qi, H., 信瑶瑶, Qin, L., Cheng, Y., & Yao, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930837
“The first clinical construct used a cytomegalovirus promoter, which is ubiquitously active and therefore drives transgene expression in antigen-presenting and non-muscle cells; this is one plausible contributor to the transgene-directed T-cell response observed in that trial (Mendell et al., 2010).”
InfluentialFunctional improvement of dystrophic muscle by utrophin gene editing
Ghosh, T., Ahamed, S. K. T., Xu, J., Han, X., Tombácz, I., Chaboub, L. S., Mitchell, M. J., Weissman, D., & Khurana, T. S. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201857
“22 Additionally, currently FDA approved therapies designed to restore dystrophin are applicable only to those patients with DMD bearing specific types of mutation and/or clinical status.”
Wang, Z., Wu, N., Fu, D., Zhao, Q., & Wang, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-71872-w
Cheng, Y. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7xs5sdb
Metadata
- Authors
- Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K. R., Li, J., Xiao, X., Samulski, J., McPhee, S. W., Samulski, R. J., & Walker, C. M.
- Affiliations
- Nationwide Children's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- AskBio (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1429-1437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3014106
- OpenAlex
- W2116885047
- Cited by
- 655
- References
- 25
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 38 · 2023: 44 · 2022: 49 · 2021: 42 · 2020: 44 · 2019: 47 · 2018: 31 · 2017: 42 · 2016: 28 · 2015: 47 · 2014: 34 · 2013: 54 · 2012: 60
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI060388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, dystrophin, autoreactive T cells, T cell immunity, dystrophin gene deletion
- MeSH terms
- Dependovirus, Autoantibodies, Child, DNA, Viral, Genetic Vectors, Humans, Immunity, Cellular, Male, T-Lymphocytes, Protein Biosynthesis, Genetic Therapy, Autoimmunity, Dystrophin, Frameshift Mutation, Muscle, Skeletal, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.